CD8A and neoplasm: Consequently, compared to patients with LUAD who are responsive to nivolumab, those resistant to the therapy exhibit higher levels of M2-TAM infiltration and reduced infiltration of CD8+ T cells and natural killer (NK) cells in the primary tumor tissues [78].